Scientific cofounders of Sinaptica.
The Promise of Personalized Neurostimulation in Slowing Alzheimer Progression: Giacomo Koch, MD, PhD; Ken Mariash; Emiliano Santarnecchi, PhD
A trio of experts from Sinaptica Therapeutics talked about recent findings presented at CTAD 2024 from a study assessing personalized transcranial magnetic stimulation in patients with Alzheimer disease. [WATCH TIME: 5 minutes]
Sweden Analysis Reveals Key Lifestyle and Socioeconomic Factors Driving Cognitive Decline
Episode 138: Training the Next Generation of Neurology Nurse Practitioners
Survey Study Aims to Assess Germany’s Readiness for Early Alzheimer Diagnosis Using Biomarkers
Cognito’s Gamma Sensory Stimulation Leads to Preserved Corpus Callosum Structure in Alzheimer Disease